Recent News

• 11.05.2025 - Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
• 11.04.2025 - Revolution Medicines to Participate in November 2025 Investor Conferences
• 10.29.2025 - Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025
• 10.27.2025 - Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
• 10.22.2025 - Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
• 10.17.2025 - Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program
• 09.29.2025 - Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
• 09.29.2025 - Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
• 09.29.2025 - Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

Recent Filings

• 11.05.2025 - EX-99.1 EX-99.1
• 11.05.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.05.2025 - 8-K Current report
• 11.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.17.2025 - 8-K Current report
• 10.17.2025 - 144 Report of proposed sale of securities
• 10.17.2025 - 144 Report of proposed sale of securities
• 10.16.2025 - 144 Report of proposed sale of securities